ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

228 OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS OPTIMIZING PHARMACEUTICAL TREATMENT IN CYSTIC FIBROSIS CHAPTER 12 [9] Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The Associa- tion of Socioeconomic Status with Outcomes in Cystic Fibrosis Patients in the United States. Am J Respir Crit Care Med. 2001;163(6):1331-7. [10] Plant BJ, Goss CH, Plant WD, Bell SC. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med. 2013;1(2):164-74. [11] Agrawal A, Agarwal A, Mehta D, Sikachi RR, Du D, Wang J. Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013. Intractable & Rare Diseases Research. 2017;6(3):191-8. [12] Heimeshoff M, Hollmeyer H, Schreyögg J, Tiemann O, Staab D. Cost of Illness of Cystic Fibrosis in Germany. PharmacoEconomics. 2012;30(9):763-77. [13] Chevreul K, Michel M, Brigham KB, López-Bastida J, Linertová R, Oliva- Moreno J, et al. Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe. Eur J Health Econ. 2016;17 Suppl 1:7-18. [14] Janssen MF, Szende A, Cabases J, Ramos-Goñi JM, Vilagut G, König HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. 2019 Mar;20(2):205-216. [15] Fiscal Sustainability of Health Systems. OECD; 2015. References [1] Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7(5):450-3. [2] Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019. [3] Mehta G, Macek M, Mehta A. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros. 2010;9:S5- S21. [4] Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen F, et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018;17(2):153-78. [5] Oates GR, Schechter MS. Socioeco- nomic status and health outcomes: cystic fibrosis as a model. Expert Rev Respir Med. 2016;10(9):967-77. [6] Madge S, Bell SC, Burgel PR, De Rijcke K, Blasi F, Elborn JS. Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. J Cyst Fibros. 2017;16(1):85-8. [7] Walicka-Serzysko K, Peckova M, Noordhoek JJ, Sands D, Drevinek P. Insights into the cystic fibrosis care in Eastern Europe: Results of survey. J Cyst Fibros. 2018;17(4):475-7. [8] Britton JR. Effects of social class, sex, and region of residence on age at death from cystic fibrosis. BMJ (Clinical research ed). 1989;298(6672):483-7.